Immunomodulatory Peptides in Research: Thymosin α1, LL-37 and KPV

Three peptides dominate the immunomodulatory corner of the research-peptide literature, and they have almost nothing in common beyond that label. Thymosin α1 is a thymic 28-mer with four decades of clinical trials behind it, cathelicidin LL-37 is a membrane-active host-defence peptide with a sharply conditional activity profile, and KPV is a three-residue fragment of α-melanocyte-stimulating hormone. None of them is part of our catalogue; this guide is a literature map for people reading or designing experiments with them, including the artefacts that make immunological peptide work unusually easy to get wrong.

Thymosin α1

Origin and chemistry

Thymosin α1 was isolated from calf thymus in 1977 and described as a heat-stable, highly acidic 28-residue polypeptide, one of several components of the crude "thymosin fraction 5" ^[1]. Its sequence, N-terminally acetylated, is Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn ^[1]; that composition gives C129H215N33O55, an average mass of 3,108.3 g/mol and a monoisotopic mass of 3,106.50 Da, which the peptide molecular weight calculator reproduces from the sequence. Its composition is six Glu and three Asp against only four Lys, and because the N-terminus is acetylated those lysines are the sole cationic groups, giving a calculated net charge near −6 at pH 7.4 — so the dilute-acetic-acid trick used to dissolve basic peptides is the wrong move here.

Whether the peptide exists in vivo was contested for years, because it was absent from extracts in which proteolysis had been blocked. A 2003 study resolved that: a lysosomal asparaginyl endopeptidase identified as legumain cleaves the Asn28–Gly29 bond of prothymosin α to release thymosin α1, which was then detected free in the cytosol of diverse mammalian tissues at concentrations similar to the precursor ^[2].

Mechanism

The dominant mechanistic account is innate-immune rather than hormonal. In mice, thymosin α1 induced functional maturation and interleukin-12 production in dendritic cells pulsed with Aspergillus fumigatus, acting through a MyD88-dependent pathway involving distinct Toll-like receptors and p38 MAPK/NF-κB signalling, and the peptide accelerated myeloid recovery and protected transplant recipients from aspergillosis ^[7]. A later review extends this to Toll-like receptor engagement in both myeloid and plasmacytoid dendritic cells with downstream cytokine production ^[8]; that review's authors were employees of the company developing the peptide, which is worth knowing when weighing its framing.

Structural work complicates any simple receptor story. By circular dichroism and NMR the peptide is unstructured in water and becomes partly structured only in membrane-mimicking environments — phospholipid vesicles, detergent micelles, or water–trifluoroethanol, where a β-turn around residues 5–8 and a helix across residues 17–24 appear ^[15]. Subsequent NMR showed interaction specifically with exposed phosphatidylserine in membrane models and in apoptotic cells, with serum albumin acting as a carrier through contacts at the peptide's C-terminal region ^[21]. For bench work the implication is practical: activity may depend on the lipid composition and protein content of the system, not on peptide concentration alone.

What the clinical record actually shows

Thymosin α1 has an unusually long therapeutic history for a research peptide. Under the non-proprietary name thymalfasin it has been described as approved in more than 35 countries for hepatitis B and C and as an immune stimulant and adjuvant ^[22]. The results behind that are mixed: pilot combination studies in hepatitis looked promising, but a large European phase III study in hepatitis C non-responders found no improvement in sustained virological response, with a reduced relapse rate among those who completed therapy ^[23].

Sepsis shows the same pattern more sharply. A six-centre single-blind trial in 361 patients with severe sepsis reported 28-day mortality of 26.0% versus 35.0% (relative risk 0.74, 95% CI 0.54–1.02) with greater improvement in monocyte HLA-DR expression in treated patients ^[24]. The definitive test followed: a double-blind, placebo-controlled phase 3 trial across 22 centres in China randomised 1,106 adults, and 28-day all-cause mortality was 23.4% with thymosin α1 against 24.1% with placebo (hazard ratio 0.99, 95% CI 0.77–1.27, P = 0.93), with no secondary or safety outcome differing significantly ^[11]. Prespecified subgroups hinted at interactions by age and diabetes, which is hypothesis-generating at best ^[11]. A promising mechanism and a null phase 3 is a common combination, and it is the single most important fact about this peptide's evidence base.

Cathelicidin LL-37

From hCAP-18 to LL-37

LL-37 is the only cathelicidin-derived antimicrobial peptide in humans ^[6]. Cloning of human CAP18 showed a 30-residue signal peptide, a 103-residue cathelin domain of then-unknown function, and a 37-residue C-terminal antimicrobial domain; synthetic CAP18(104–140) bound lipopolysaccharide-coated erythrocytes, inhibited LPS-induced nitric oxide release from macrophages and tissue-factor generation, and protected mice from LPS lethality ^[3]. Release of the active peptide is extracellular and protease-specific: hCAP-18 is not cleaved inside neutrophils after phagocytosis, but is cleaved to LL-37 in exocytosed material by proteinase 3 ^[4]. The peptide and its precursor are expressed in neutrophils and in epithelia of skin, gut and airway ^[6].

Activity is conditional, not intrinsic

The most useful single paper for anyone planning LL-37 experiments is a 1998 conformational study. In water the peptide is disordered; bicarbonate, sulfate or trifluoroacetate at 15 mM drive helix formation, while 160 mM chloride does so less efficiently; helicity correlates with antibacterial activity against Gram-positive and Gram-negative organisms; the minimal inhibitory concentration against E. coli was 5 µM; 13–25 µM was cytotoxic to several eukaryotic cell types; and human serum inhibited both activities ^[16]. Two consequences follow. First, the buffer is part of the experiment — and because trifluoroacetate is one of the helix-promoting anions, the residual counter-ion from purification is not an inert passenger. Second, the therapeutic window between bacterial killing and host-cell toxicity is about three- to fivefold in vitro.

Serum inhibition has a named mechanism: apolipoprotein A-I is the principal LL-37 binding protein in human plasma, binding with an apparent dissociation constant in the low micromolar range, and antibodies against apoA-I block most of the plasma inhibition ^[17]. Bacterial proteases matter too. Staphylococcus aureus aureolysin cleaves LL-37 at Arg19–Ile20, Arg23–Ile24 and Leu31–Val32 and abolishes its antibacterial activity, whereas the V8 glutamyl endopeptidase cleaves only Glu16–Phe17, leaving a C-terminal fragment (LL-17-37) with activity comparable to the full peptide ^[18]. Any culture assay with a protease-secreting organism is therefore measuring a mixture.

Immunomodulation, including the unwelcome kind

Beyond membrane activity, LL-37 is chemotactic for human neutrophils, monocytes and T cells and mobilises calcium through formyl peptide receptor-like 1 ^[9], and reviews catalogue roles in LPS neutralisation and re-epithelialisation ^[6]. The same chemistry has a pathological face: by binding self-DNA into aggregated, condensed complexes that are retained in early endosomes, LL-37 converts inert human DNA into a trigger for Toll-like receptor 9 and type I interferon production in plasmacytoid dendritic cells, a mechanism identified in psoriasis ^[25]. A peptide that breaks innate tolerance to self-DNA is not a straightforward "natural antibiotic".

Clinical testing has been modest and the results instructive. A first-in-human study in 34 participants with hard-to-heal venous leg ulcers reported healing rate constants roughly six- and three-fold higher than placebo at 0.5 and 1.6 mg/mL (P = 0.003 and P = 0.088) with no effect at 3.2 mg/mL ^[12] — a non-monotonic dose pattern consistent with the cytotoxicity ceiling above. The follow-up phase IIb trial in 148 patients found no significant healing improvement in the full population; only a post-hoc subgroup with wounds of at least 10 cm² showed benefit on several interrelated parameters ^[13].

KPV, the α-MSH C-terminal tripeptide

KPV is Lys-Pro-Val, the C-terminal tripeptide of the 13-residue α-melanocyte-stimulating hormone, formally α-MSH(11–13) ^[5]. As a free acid it is C16H30N4O4 with an average mass of 342.4 g/mol — small enough that solubility and aggregation problems largely disappear, and small enough that synthesis quality, not sequence difficulty, determines what is in the vial.

Its pharmacology is split between receptor and transporter. KPV binds MC1R and, like the parent hormone, modulates antigen-presenting cell function; systemic and topical application inhibited both sensitisation and elicitation phases of contact hypersensitivity in mice ^[5]. In keratinocytes, however, neither α-MSH nor KPV raised cyclic AMP, and calcium responses appeared only when the cAMP pathway was inhibited, though MC1R-transfected CHO cells did respond with calcium elevation ^[26] — a reminder that cell background governs which signal is seen. The transporter route is better defined: nanomolar KPV inhibited NF-κB and MAP kinase signalling and reduced pro-inflammatory cytokine secretion in human intestinal epithelial and T cell lines, uptake was competitive with PepT1 substrates, and oral KPV reduced dextran sodium sulfate- and TNBS-induced colitis in mice ^[10].

Colitis models are the peptide's home ground. KPV improved weight recovery, histology and colonic myeloperoxidase activity in dextran sodium sulfate colitis and in CD45RBhi transfer colitis, and still protected mice carrying a non-functional MC1R ^[14]. Delivery work then showed how much of the apparent potency is a pharmacokinetic matter: encapsulated in polymeric nanoparticles within an alginate–chitosan hydrogel, KPV matched the efficacy of free peptide at a 12,000-fold lower concentration ^[27]. Reported effective concentrations are properties of the delivery system as much as of the molecule.

Evidence quality at a glance

For the bench

• Control for endotoxin before believing an immune readout. Lipopolysaccharide was a frequent and significant contaminant of commercial-grade synthetic peptide preparations in a systematic survey, and polymyxin B abolished much of the apparent activity ^[19]. An endotoxin measurement and a polymyxin B arm cost less than a retracted conclusion.
• Treat the counter-ion as a variable. Trifluoroacetate at 10⁻⁸–10⁻⁷ M reduced proliferation of osteoblasts, chondrocytes and calvarial cultures, and TFA salts of amylin and calcitonin gave different answers from their hydrochloride salts ^[20]; for LL-37 the same anion also promotes the active helix ^[16]. Record the salt form from the batch documentation and keep it constant across arms.
• Match the vehicle to the charge. Thymosin α1 is strongly acidic and KPV is small and polar, so neutral water or buffer suits both; the solubility troubleshooting guide covers stubborn cases, and storage practice applies unchanged to all three peptides.
• Expect proteolysis in serum-containing media. LL-37 is cleaved and inactivated by a staphylococcal metalloprotease ^[18], thymosin α1 is a linear unprotected peptide ^[1], and KPV is a PepT1 substrate ^[10]. Verify intact peptide at the end of an incubation rather than assuming it.
• Bracket cytotoxicity around every antimicrobial result. The 5 µM MIC and 13–25 µM cytotoxic range for LL-37 ^[16] should be measured in your own cells and medium; serum-free and serum-containing arms will differ ^[17].
• Read the synthesis route. Deletion, insertion and side-chain-adduct impurities are intrinsic to solid-phase peptide synthesis and matter most for the longest of these sequences; how peptides are made covers the chemistry, and the neuropeptides guide takes the same approach to DSIP, oxytocin and kisspeptin.